Add Company
Join Now

NeoImmuneTech Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • NeoImmuneTech's estimated annual revenue is currently $11.5M per year.(i)
  • NeoImmuneTech's estimated revenue per employee is $155,000

Employee Data

  • NeoImmuneTech has 74 Employees.(i)
  • NeoImmuneTech grew their employee count by 9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.3M2-60%N/AN/A
#2
$2.9M38-31%$17.5MN/A
#3
$2.9M38-33%$10.5MN/A
#4
$19.8M1280%$69.4MN/A
#5
$9.6M62-15%N/AN/A
#6
$1.4M90%N/AN/A
#7
$2.5M160%N/AN/A
#8
$7.4M480%N/AN/A
#9
$0.2M1-83%N/AN/A
#10
$1.7M1122%N/AN/A
Add Company

What Is NeoImmuneTech?

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials. Follow us on Twitter @neoimmunetech

keywords:N/A

N/A

Total Funding

74

Number of Employees

$11.5M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$18.6M7432%N/A
#2
$18M7410%N/A
#3
$18M7419%N/A
#4
$21.8M741%N/A
#5
$14.7M74-6%N/A